CSLCSLLY -2.30%73 9-Day RSI is 63.65 as of Jun. 27, 2026. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $50.49 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 1,425 Biotechnology companies, CSL ranks worse than 92.7% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-06-27), CSL's 9-Day RSI is 63.65.
The industry rank for CSL's 9-Day RSI or its related term are showing as below:
CSLLY's 9-Day RSI is ranked worse than 92.7% of 1425
companies
in the Biotechnology industry
Industry Median: 45
vs CSLLY: 63.65
CSL (OTCPK:CSLLY) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
CSL 9-Day RSI Related Terms
CSLLY vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, CSL's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where CSL's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL (CSLLY) has a 9-Day RSI of 63.65 as of Jun. 27, 2026. According to the industry distribution chart, CSL ranks #1321 out of 1425 companies in the Biotechnology industry, placing it in the top 92.7%.
Is CSL's 9-Day RSI too high?
CSL's current 9-Day RSI is 63.65. The Biotechnology industry median 9-Day RSI is 45.00. CSL's value of 63.65 is 41.4% above this industry median. Based on the distribution chart, CSL ranks #1321 out of 1425 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #1321 out of 1425 companies for 9-Day RSI. This places CSL in the lower half of its industry. The industry median 9-Day RSI is 45.00. CSL's value of 63.65 is 41.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 45.00, based on 1,425 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current 9-Day RSI of 63.65 is 41.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 45.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current 9-Day RSI is 63.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.49, compared to a current price of $19.98 — trading 60.4% below its estimated fair value. The current 9-Day RSI is 63.65 and 41.4% above the Biotechnology industry median of 45.00. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For CSL (CSLLY), the current 9-Day RSI is 63.65 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $19.98 is trading 60.4% below its estimated GF Value™ of $50.49.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
9-Day RSI: 63.65
GF Value™: $50.49 vs. price of $19.98 (60.4% below fair value)
Industry Position: 41.4% above the Biotechnology median (#1321 of 1425)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 